收藏切换
Comparison of sodium-glucose linked transporter 2 inhibitors approved in China
收藏切换
Xiaoying XU1, Xingyun HOU2, Yuzhen LI1, Nianxi YU2, Jiaoyang ZHENG3, *
World Clinical Drug | 2022, 43(6) : 663 - 670
Less
收藏切换
World Clinical Drug | 2022, 43(6): 663-670
• Topic •
Comparison of sodium-glucose linked transporter 2 inhibitors approved in China
Full
Xiaoying XU1, Xingyun HOU2, Yuzhen LI1, Nianxi YU2, Jiaoyang ZHENG3, *
Affiliations
  • 1.Department of Pharmacy, the Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen 518033, Guangdong Province, China
  • 2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China
  • 3.Department of Health Management, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China
Published: 2022-06-10 doi: 10.13683/j.wph.2022.06.003
Outline
收藏切换

Sodium-glucose linked transporter 2 (SGLT2) inhibitors are a new class of anti-diabetes mellitus (DM) drugs. SGLT2 is usually involved in the reabsorption of about 90% of the glucose filtered by the glomerular. SGLT2 inhibitors directly reduce blood sugar by inhibiting the active transport of glucose by SGLT2, inhibiting the reabsorption of glucose by the kidneys, increasing urinary glucose excretion. SGLT2 inhibitors are becoming increasingly important in the treatment of type 2 DM (T2DM), as they can not only reduce blood glucose, but also have cardio-renal protective effects. SGLT2 inhibitors have been widely used after being marketed in China. Now, the pharmacokinetic characteristics, hypoglycemic effect, cardiovascular protection, renal protection and adverse reactions of SGLT2 inhibitors that have been listed in China were compared in order to provide reference for clinical medication.

sodium-glucose linked transporter 2 inhibitor  /  dapagliflozin  /  empagliflozin  /  canagliflozin  /  ertugliflozin
徐小英, 侯幸赟, 李玉珍, 余年喜, 郑骄阳. 国内上市的钠-葡萄糖耦联转运体2抑制剂的比较. 世界临床药物, 2022 , 43 (6) : 663 -670 . DOI: 10.13683/j.wph.2022.06.003
Xiaoying XU, Xingyun HOU, Yuzhen LI, Nianxi YU, Jiaoyang ZHENG. Comparison of sodium-glucose linked transporter 2 inhibitors approved in China[J]. World Clinical Drug, 2022 , 43 (6) : 663 -670 . DOI: 10.13683/j.wph.2022.06.003
Year 2022 volume 43 Issue 6
14
3
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.06.003
  • Receive Date:2021-12-01
  • Online Date:2026-11-19
  • Published:2022-06-10
Article Data
Affiliations
History
  • Received:2021-12-01
  • Revised:2022-04-12
Funding
Affiliations
    1.Department of Pharmacy, the Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen 518033, Guangdong Province, China
    2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China
    3.Department of Health Management, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.06.003
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT